BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

BioNTech (NASDAQ: BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

ROCKVILLE, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, and AcroImmune, a ...

OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger. Both cancer biotechs were co-founded by OncoC4 CEO Yang Liu, Ph.D., and ...

Sept. 25, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, and AcroImmune, a biopharmaceutical company developing immunotherapy ...

Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the ...

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

The European stock markets closed mostly higher on Friday as the Stoxx Europe 600 gained 0.19%, the Swiss Market Index was up 0.18%, France's CAC rose 0.39%, Germany's increased 0.38%, while the FTSE ...

BioNTech (Nasdaq: BNTX) and partner USA-based OncoC4 understand that the partial clinical hold in the ongoing Phase III trial ...

OncoC4, Pfizer and Regeneron. For more information, please visit www.BioNTech.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation ...

Omicron KP.2 variant adapted vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks. The updated ...